Logo
Search
Sign Up

The Pulse Check

Emyria (ASX: EMD)

+1

My Second Armchair Pick: Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

My Second Armchair Pick: Emyria (ASX: EMD)

Jason Segal
Jason Segal

Telix (ASX: TLX)

+1

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Apr 17, 2026

•

9 min read

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Jason Segal
Jason Segal

The Pulse Check

+2

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Riding the Peptidal Wave: Biotech Bounce Back

Jason Segal
Jason Segal

The Pulse Check

+1

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Jason Segal
Jason Segal

The Pulse Check

+1

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

When Shares Become the Vote: The 249D-ilemma

Jason Segal
Jason Segal

Telix (ASX: TLX)

+1

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

Telix lights up the deal docket for the ASX biotech sector

Jason Segal
Jason Segal

The Pulse Check

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

While everyone is selling. Big Pharma is buying.

Jason Segal
Jason Segal

The Pulse Check

Market’s Rocking: A Green Day

Apr 9, 2026

•

6 min read

Market’s Rocking: A Green Day

Jason Segal
Jason Segal

The Pulse Check

+1

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Apr 8, 2026

•

15 min read

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Jason Segal
Jason Segal

The Pulse Check

+1

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Jason Segal
Jason Segal

The Pulse Check

+1

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Mar 31, 2026

•

18 min read

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Jason Segal
Jason Segal

The Pulse Check

+1

Why Peptides Are Suddenly Everywhere

Mar 30, 2026

•

9 min read

Why Peptides Are Suddenly Everywhere

Jason Segal
Jason Segal

Lumos Diagnostics (ASX: LDX)

+1

Crowned then Clipped: When the Raise Gets There Before the Rally

Mar 27, 2026

•

6 min read

Crowned then Clipped: When the Raise Gets There Before the Rally

Jason Segal
Jason Segal

Lumos Diagnostics (ASX: LDX)

+1

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Mar 26, 2026

•

9 min read

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Jason Segal
Jason Segal

The Pulse Check

Why Iran Matters for Biotech Investors

Mar 25, 2026

•

5 min read

Why Iran Matters for Biotech Investors

Jason Segal
Jason Segal

The Pulse Check

+1

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Mar 24, 2026

•

17 min read

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Jason Segal
Jason Segal

Amplia (ASX: ATX)

+1

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Mar 23, 2026

•

7 min read

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Jason Segal
Jason Segal

Amplia (ASX: ATX)

+1

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Mar 20, 2026

•

10 min read

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Jason Segal
Jason Segal

The Pulse Check

+1

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Mar 19, 2026

•

15 min read

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Jason Segal
Jason Segal

The Pulse Check

Flash update on my day trip to Brisbane

Mar 18, 2026

•

3 min read

Flash update on my day trip to Brisbane

Jason Segal
Jason Segal

The Pulse Check

Medical Device Playbook: From FDA Clearance to Commercial Success

Mar 17, 2026

•

16 min read

Medical Device Playbook: From FDA Clearance to Commercial Success

Jason Segal
Jason Segal

The Pulse Check

First pick flying, plus my plans for the Armchair Portfolio

Mar 16, 2026

•

7 min read

First pick flying, plus my plans for the Armchair Portfolio

Jason Segal
Jason Segal

The Pulse Check

+1

My First Armchair Pick: Tetratherix (ASX: TTX)

Mar 16, 2026

•

24 min read

My First Armchair Pick: Tetratherix (ASX: TTX)

Jason Segal
Jason Segal

The Pulse Check

+1

The Curse of the Friday the 13th

Mar 13, 2026

•

4 min read

The Curse of the Friday the 13th

Jason Segal
Jason Segal

The Pulse Check

+1

A Nervous Wait for the Immutep Results

Mar 12, 2026

•

5 min read

A Nervous Wait for the Immutep Results

Jason Segal
Jason Segal
Load more

The Armchair Analyst

© 2026 The Armchair Analyst.
Report abusePrivacy policyTerms of use
beehiivPowered by beehiiv